Lantern Pharma Inc. (NASDAQ: LTRN) announced the commercial launch of withZeta.ai, an artificial intelligence platform designed for rare cancer drug discovery and development. The platform is now available through subscription tiers including introductory, academic, and commercial access levels.

The company will debut the platform at two events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research Annual Meeting in San Diego from April 17-22, 2026.

WithZeta.ai represents an evolution of Lantern's RADR platform technology, which the company has used for its own cancer drug development programs. The platform features multi-agentic AI architecture and incorporates a proprietary oncology database covering 438 cancer types. It offers three research modes: Explorer, Investigator, and Reporter.

The platform includes specialized capabilities such as blood-brain barrier penetration prediction and molecular design features. Users can query clinical trial databases, scientific literature, and molecular databases simultaneously through the system.

"WithZeta.ai was forged in the crucible of real rare cancer drug development," said Panna Sharma, President and Chief Executive Officer of Lantern Pharma. "Our RADR AI platform taught us what it means to build AI that actually works in the most challenging corners of oncology."

The subscription model aims to create a new revenue stream for Lantern Pharma shareholders. Subscriptions are available at withzeta.ai, with enterprise partnership inquiries directed to the company's investor relations contact.

Lantern Pharma currently has three drugs in clinical trials and has received 12 FDA designations across orphan, pediatric rare disease, and fast track classifications. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.